Composite age + comorbidity exclusion from CAR-T: age ≥75 with Charlson Comorbidity Index...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-CAR-T-INELIGIBLE-AGE-COMORBID |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-TRANSCEND-NHL-001-ABRAMSON-2020 SRC-ZUMA-1-NEELAPU-2017 |
Red Flag Origin
| Definition | Composite age + comorbidity exclusion from CAR-T: age ≥75 with Charlson Comorbidity Index ≥4, OR age ≥80 regardless of comorbidity (real-world median for CRS/ICANS mortality jump), OR significant cognitive impairment (MMSE ≤24 or documented dementia) precluding ICANS toxicity recognition and informed consent. |
|---|---|
| Clinical direction | hold |
| Category | fitness-eligibility |
Trigger Logic
{
"any_of": [
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 75
},
{
"comparator": ">=",
"finding": "charlson_score",
"threshold": 4
}
]
},
{
"comparator": ">=",
"finding": "age",
"threshold": 80
},
{
"all_of": [
{
"comparator": "<=",
"finding": "mmse_score",
"threshold": 24
}
]
},
{
"finding": "cognitive_impairment_significant",
"value": true
}
],
"type": "composite_score"
}
Notes
ZUMA-1, TRANSCEND, JULIET enrolled patients up to age 76-77; real-world experience (CIBMTR, French DESCAR-T) shows acceptable safety to age 80 with selected fit patients but >80 carries 2-3x higher non-relapse mortality. Cognitive baseline matters because ICANS presents as encephalopathy (ICE score, hand-writing) — pre-existing dementia obscures detection. Liso-cel (TRANSCEND) had broadest age tolerability in trials due to favorable CRS profile. Frail-elderly alternatives: bispecifics (epcoritamab, glofitamab — outpatient escalation feasible) gaining ground. Distinguish from RF-CAR-T-INELIGIBLE-ORGAN (organ-driven) and RF-FRAILTY-AGE-G8-LOW (general geriatric flag).
Used By
Algorithms
ALGO-MCL-2L- ALGO-MCL-2L
Red flag
RF-DLBCL-CART-INELIGIBLE-POST-2L- Relapsed/refractory DLBCL post ≥2 prior systemic therapies, NOT a candidate for anti-CD19...RF-DLBCL-CD20-POS-EPCORITAMAB-CANDIDATE- Relapsed/refractory DLBCL with confirmed CD20 expression on malignant B-cells, post ≥2 pr...RF-DLBCL-CD20-POS-GLOFITAMAB-CANDIDATE- Relapsed/refractory DLBCL with confirmed CD20 expression on malignant B-cells, post ≥2 pr...